Results 61 to 70 of about 4,448 (207)
Catastrophic antiphospholipid syndrome: CAPS
Japanese Journal of Clinical Immunology, 2005 Antiphospholipid syndrome (APS) is well known as an autoimmune thrombotic syndrome with recurrent thromboses. In APS, thromboses occurs both artery and vein, and from large to micro vessels. In contrast, so called catastrophic antiphospholipid syndrome, CAPS, develops multiple thromboses at microvessels mainly within a few weeks and induces to poor ...
openaire +3 more sources
On the occasion of world hypertension day 2014: A nephrology point of view [PDF]
, 2014 Hypertension is a major risk factor for myocardial infarction, heart failure, stroke, peripheral arterial disease, and aortic aneurysm, and is a cause of chronic kidney disease.
Ardalan, Mohammadreza. +2 more
core +5 more sources
The diagnosis and management of the haematologic manifestations of lupus [PDF]
, 2016 Haematological manifestations in systemic lupus erythematosus (SLE) are frequently observed. They are diverse and range from mild to severe.
Castro, SG +2 more
core +1 more source
Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities
Arthritis &Rheumatology, Volume 77, Issue 12, Page 1626-1634, December 2025.Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley +1 more source
Catastrophic Antiphospholipid Syndrome
Rheumatology News, 2011 Antiphospholipid syndrome (APS) is characterized by the development of arterial and/or venous thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies (aPL) anticardiolipin (aCL), anti-β2-glycoprotein I (anti-β2GPI), and lupus anticoagulant (LA).
Maria J. Cuadrado +3 more
openaire +2 more sources
Stratification of responders towards eculizumab using a structural epitope mapping strategy [PDF]
, 2016 The complement component 5 (C5)-binding antibody eculizumab is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS).
Berglund, Magnus M. +6 more
core +1 more source
Case Reports in Medicine, 2012 Microangiopathic antiphospholipid-associated syndromes (MAPSs) are reported as encompassing several conditions mainly affecting the microvasculature of selected organs: the liver in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet ...
Nobuhiro Suzumori +5 more
doaj +1 more source
Advanced Science, Volume 12, Issue 41, November 6, 2025.This study uncovers a novel mechanism and therapeutic targets in obstetric antiphospholipid syndrome (OAPS). Antiphospholipid antibody/ß2‐glycoprotein I complex boosts CCL2 and TNF‐α expression in decidual macrophages via TLR4‐NF‐κB. CCL2 accumulates on endothelial surfaces via ACKR1, recruiting monocyte‐derived CCR2+ macrophages, driving inflammation,
Rui Gao +13 more
wiley +1 more source
American Journal of Hematology, Volume 100, Issue 11, Page 1972-1982, November 2025.ABSTRACT Only few data are available regarding the efficacy and safety of thrombopoietin receptor agonists (TPO‐RAs) for treating systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS)‐associated immune thrombocytopenia (ITP). We retrospectively assessed the efficacy and safety of TPO‐RAs in 80 adults with ITP in three subgroups: (1)
Cindy Marques +17 more
wiley +1 more source
Flare of Antiphospholipid Syndrome in the Course of COVID-19
TH Open, 2020 We report the case of a 48-year-old man followed since 2013 for primary antiphospholipid syndrome (APLS) revealed by venous thromboembolism in the presence of antiphospholipid antibodies (APL-Abs, anticardiolipin and anti-β-2-glycoprotein-1), who ...
Alexandre Thibault Jacques Maria +6 more
doaj +1 more source